 |
|
Cholinesterase Inhibitors for Alzheimer Disease—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: We agree with Drs van Gool and Lemstra that certain patients may respond preferentially to ChIs. Indeed this may be true for both the cognitive and neuropsychiatric symptoms. For example, it may be that certain genetic or environmental factors determine whether patients with AD respond to ChIs or influence the amount of their response. Similarly, Dr Finucane's comments regarding the importance of assessing caregiver burden or quality of life are especially important. Unfortunately, we were unable to identify subsets of patients or quantify the effects of ChIs on quality of life or caregiver burden due to lack of data presented in the primary trials. Nonetheless, as we stated in our article, we feel these are important areas for future investigation.
Given that ChIs have already been used in clinical practice for neuropsychiatric symptoms, the goal of our meta-analysis was to synthesize all the available data and quantify the . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Cholinesterase Inhibitors for Alzheimer Disease
Willem A. van Gool and Afina W. Lemstra
JAMA. 2003;289(18):2359.
EXTRACT
| FULL TEXT
Cholinesterase Inhibitors for Alzheimer Disease
Thomas E. Finucane
JAMA. 2003;289(18):2359.
EXTRACT
| FULL TEXT
Cholinesterase Inhibitors for Alzheimer Disease
Lon S. Schneider
JAMA. 2003;289(18):2359-2360.
EXTRACT
| FULL TEXT
Cholinesterase Inhibitors for Alzheimer Disease
Sean Lilienfeld
JAMA. 2003;289(18):2360.
EXTRACT
| FULL TEXT
|
